PATENT CLAIM ANALYSIS

Application Number: 16228835
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "253120"]

Abstract:
Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK 1 ) receptor. The compounds have the general formula (I):

Claim (Index 17):
The method of  claim 11 , wherein said compound or a pharmaceutically acceptable salt thereof, is intravenously administered at a dosage of from about 10 mg to about 200 mg based on the netupitant portion of the molecule.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 98.0
- Lexical Diversity: 1.19355
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15194984', '15874325', '14360991', '12637719', '11582293']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8053801785519137
- 35 USC 102 Novelty (BERT): 0.5424414727944885
- Combined Prediction Score: 0.7790863079761712
- Mean Citation Score: 329.305366
- Max Citation Score: 397.34216
- Similarity Product: 281.8709987517166

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test